Cannabis Science Reports Two Cannabis-based Drug Release Programs

Programs focused on H1N1 Swine flu, H1N5 Avian flu, and PTSD
Cannabis Science has completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis drug medicines for FDA clinical trials. The company has determined that it will have more than one product in clinical testing and trials at the same time.

This news comes following the identification of two distinct parallel paths in developing pharmaceutical products for FDA approval. The first program being the H1N1 Swine flu and the H1N5 Avian flu, and the second being a newly formed initiative for Veterans who suffer from Post Traumatic Stress Disorder (PTSD).

The company looks forward to announce its continued progress with these initiatives through the development of an online progress chart.

Robert Melamede, president and CEO of Cannabis Science, said: “Times are changing. There is an ever-increasing demand for our cannabis-based drugs, and this demand is growing exponentially throughout the United States and the rest of the world. Modern science supports the public demand for cannabis-based FDA approved drug products that reduce the impact of critical life altering illnesses."

"The public need for our products drives our efforts to rapidly move our drugs through all available regulatory channels. We believe this enormous public demand on a global scale is a major key to our success and we are very excited to be positioned to provide solutions. We are currently sourcing cGMP compliant facilities to produce our initial formulations for FDA compliant testing," he added.

source: http://www.pharmaceutical-business-review.com/